Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects

Current Medical Research and Opinion

Volumn 33, Issue 2, 2017, Pages 225-229

  Bays, Harold ^a   Pi Sunyer, Xavier ^b   Hemmingsson, Joanna Uddén ^c   Claudius, Birgitte ^d   Jensen, Christine B ^d   Van Gaal, Luc ^e  

^a Louisville Metab Atherosclerosis R   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d NOVO NORDISK A S   (Denmark)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antiobesity medications; GLP 1 receptor agonist; liraglutide; obesity therapy; randomized clinical trial

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGED; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84994130135     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1251892     Document Type: Article

References (18)

1. American Society for Metabolic and Bariatric Surgery, Obesity Society, American Society of Bariatric Physicians, American Association of Clinical Endocrinologists. Joint press release:obesity is a disease:leading obesity groups agree. PRNewswire website. 2013. Available at:http://www.prnewswire.com/news-releases/obesity-is-a-disease-leading-obesity-groups-agree-212194851.html [Last accessed 15 December 2015]
2. Bays H, Scinta W., Adiposopathy and epigenetics:an introduction to obesity as a transgenerational disease. Curr Med Res Opin 2015;31:2059-69
3. Khaodhiar L, McCowen KC, Blackburn GL., Obesity and its comorbid conditions. Clin Cornerstone 1999;2:17-31
4. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight:a systematic review and meta-analysis. BMC Public Health 2009;9:88
5. Warkentin LM, Das D, Majumdar SR, et al. The effect of weight loss on health-related quality of life:systematic review and meta-analysis of randomized trials. Obes Rev 2014;15:169-82
6. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-9
7. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. Int J Obes 2014;38:784-93
8. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
9. Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes:the SCALE diabetes randomized clinical trial. JAMA 2015;314:687-99
10. Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea:the SCALE Sleep Apnea randomized clinical trial. Int J Obes (London) 2016:published online 23 March 2016, doi:10.1038/ijo.2016.52
11. Wadden TA, Hollander P, Klein S, et al. on behalf of the NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss:the SCALE maintenance randomized study. Int J Obes 2013;37:1443-51
12. Baron RM, Kenny, DA., The moderator–mediator variable distinction in social psychological research–conceptual, strategic, and statistical considerations. J Personality Social Psychol 1986;51:1173-82
13. Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity 2016; doi:10.1002/oby.21629
14. Bays HE., Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease:treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol 2012;110:4-12B
15. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-54
16. Gallagher D, Heshka S, Kelley DE, et al.; MRI Ancillary Study Group of Look AHEAD Research Group. Changes in adipose tissue depots and metabolic markers following a 1-year diet and exercise intervention in overweight and obese patients with type 2 diabetes. Diabetes Care 2014;37:3325-32
17. Bays H., Adiposopathy, “sick fat,” Ockham’s razor, and resolution of the obesity paradox. Curr Atheroscler Rep 2014;16:409
18. Klöting N, Blüher M., Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord 2014;15:277-87